| Title |
The therapeutic efficacy of propranolol in children with recurrent primary epistaxis
|
|---|---|
| Published in |
Drug Design, Development and Therapy, March 2013
|
| DOI | 10.2147/dddt.s41756 |
| Pubmed ID | |
| Authors |
Bojko Bjelakovic, Mila Bojanovic, Stevo Lukic, Ljiljana Saranac, Vladislav Vukomanovic, Sergej Prijic, Nikola Zivkovic, Dusica Randjelovic |
| Abstract |
We hypothesized that some characteristics of beta-blockers, including negative inotropic, peripheral vasoconstrictor, and antiangiogenic effects, might be potentially useful in treating children with epistaxis. From June 2010 to March 2012, a total of seven children with recurrent primary epistaxis resistant to conventional management were observed at our institution. An overall effectiveness of propranolol was noted in all seven children when given a dose of 1.5-2 mg/kg/day (divided into three doses) as a second line therapy for terminating epistaxis. Based on our first experience, we believe that propranolol could be a favorable treatment option for patients with primary epistaxis. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 5% |
| Unknown | 18 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 16% |
| Student > Postgraduate | 3 | 16% |
| Student > Doctoral Student | 2 | 11% |
| Researcher | 2 | 11% |
| Professor > Associate Professor | 2 | 11% |
| Other | 4 | 21% |
| Unknown | 3 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 37% |
| Biochemistry, Genetics and Molecular Biology | 3 | 16% |
| Agricultural and Biological Sciences | 1 | 5% |
| Nursing and Health Professions | 1 | 5% |
| Social Sciences | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 5 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 March 2013.
All research outputs
#20,823,121
of 25,584,565 outputs
Outputs from Drug Design, Development and Therapy
#1,416
of 2,254 outputs
Outputs of similar age
#159,453
of 206,591 outputs
Outputs of similar age from Drug Design, Development and Therapy
#15
of 22 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,254 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 24th percentile – i.e., 24% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,591 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.